Azer-cel Granted FDA Fast Track Designation in Blood Cancer
Filed with ASX · · 3 pages · English
Story so far
Earlier from Imugene
- S&P DJI Announces March 2025 Quarterly Rebalance
- Imugene Granted India Patent for Oncolytic Virotherapy CF33
- Imugene OnCARlytics Patent Allowance in China
- Azer-cel demonstrates two additional Complete Responses
- Imugene Receives A$20 million for Convertible Notes Issuance
Later from Imugene
- Notice of Extraordinary General Meeting/Proxy Form
- Two Additional Complete Responses in azer-cel Ph1b trial
- Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
- Imugene Completes $22.5M Placement and c.$15M SPP
- Imugene Capital Raising Presentation
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene